No COVID-19 surge, only sporadic cases reported in India: Health experts
Dr Suranjit Chatterjee, Senior Consultant in Internal Medicine at Indraprastha Apollo Hospital, said on Friday, "At the moment, the situation is under control. There are, at most, sporadic cases, which are also rare. Even the present cases are being managed very easily."
"They are not being hospitalised. This is what we were expecting: that when COVID happened, it would remain a seasonal flu which could be treated very easily. The situation is not one of panic..." He further said.
"We haven't seen any hospitalised or ICU Covid-19 cases in the hospital. Only hype has been created, but there is no need to panic," he said.
Additionally, Dr Dhiren Gupta, Co-Director, Paediatric Intensive Care Unit, Sir Gangaram Hospital explained, "We have come to know that COVID is increasing, especially in Southeast Asia. But many patients are coming with body aches, nonspecific, fever, cold, so off late, we may start testing. But presently, you know that screening is being done with 257 cases testing positive. I think this is just the tip of the iceberg. There must be many cases."
"I think it's been 2022 onward. We have never seen major problem in any age group, except for those less than one year old. When Omicron started, it created a little bit of a problem in babies less than one year old, not beyond that," he said.
Given the recent surge in COVID-19 cases in various parts of the country, the Delhi government has issued an advisory directing all hospitals to ensure preparedness for the availability of beds, oxygen, and medicines.
According to the Office of the Health Minister of the Delhi government, the Health Department of Delhi has released a precautionary advisory stating that this was for routine surveillance and there is no cause for concern. The health department assured that they are committed to monitoring the situation.
The advisory urged all health institutions to send positive samples for genome sequencing to Lok Nayak Hospital to facilitate early detection of any new variants.
"In view of the recent increase in COVID-19 cases, it is reiterated that all medical directors, medical superintendents, administrators of all government and private hospitals should ensure hospital preparedness."
It also said that all the equipment, such as ventilators, BiPAP, oxygen concentrators, psa et, etc., must be in functional condition and refresher training of dedicated staff must be conducted.The advisory said that Influenza-like Illness (ILI) and Severe Acute Respiratory Illness (SARI) cases in all health facilities (OPD/IPD) must be reported daily on the Integrated Health Information Platform (IHIP) portal.
Additionally, confirmed influenza and COVID-19 cases may also be reported on the IHIP under the L form. All parameters must be reported daily on the Delhi State Health Data Management Portal. The advisory called for adequate testing as per the COVID-19 testing guidelines and to ensure COVID-19 testing of 5 per cent ILI cases and 100 per cent SARI cases. ICMR guidelines for testing are attached.
It also asked to send all positive COVID-19 samples for Whole Genome Sequencing to LokNayak Hospital so as to enable timely detection of new variants, if any and share the number of samples sent for WGS with the State Surveillance Unit."Respiratory etiquette is being followed, including wearing a mask on hospital premises and in health facilities," it said further.
As of May 19, 2025, the number of active COVID-19 cases in India stands at 257 -- a very low figure considering the country's large population. Almost all of these cases are mild, with no hospitalisation required. The country also has a robust system for surveillance of respiratory viral illnesses, including COVID-19, through the Integrated Disease Surveillance Programme (IDSP) and the ICMR.
The Union Health Ministry remains vigilant and proactive in monitoring the situation closely, ensuring that appropriate measures are in place to safeguard public health. While COVID-19 is now considered another type of viral infection, basic precautions such as hand hygiene, masks in crowded areas and avoiding unnecessary gatherings are still encouraged, the statement said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times of Oman
6 days ago
- Times of Oman
Philippines accelerates TB elimination drive with India's community-based screening devices
New Delhi: The Philippines, one of the top five countries with the highest tuberculosis (TB) burden, faces the challenge of detecting and treating an estimated 1,90,000 missed TB cases each year, an official statement said. In line with the United Nations target to find and treat 2.1 million Tuberculosis cases in the country by 2027, the Philippines' Health Department is stepping up its commitment to strengthen community-level screening and diagnosis through India-made innovative Truenat® systems and ultra-portable X-ray devices. Currently, there are 68 Truenat® devices deployed across the Philippines, enabling rapid, multi-disease molecular testing for TB, HIV, HPV, Hepatitis B & C, and more. A pilot in the Bantayan Islands demonstrated the transformative potential of the platform, achieving a remarkable 1008% increase in TB case detection, as per the statement. Molbio's WHO-endorsed and ICMR-approved solutions for TB detection address critical barriers in the Philippines, such as geographic isolation, underutilization of laboratory testing, and limited access in rural and island communities. The recent approval of the PRORAD Atlas Ultraportable X-ray by the Philippines FDA paves the way for integrated, end-to-end TB screening and diagnosis, ensuring immediate linkage to treatment. Health Secretary of the Philippines Theodore J Herbosa said, "As we intensify our efforts to combat tuberculosis (TB) in the Philippines, the collaboration with India stands as a beacon of innovation and partnership. The integration of India's indigenous diagnostic technologies, such as the Truenat® system, into our healthcare infrastructure is pivotal. Truenat®, known for its rapid and reliable molecular diagnostic capabilities, allows for swift and accurate TB screenings, enhancing our capacity to manage and eventually eliminate TB within our borders, especially in remote areas." "This collaboration is part of a broader strengthening bilateral relationship between India and the Philippines, which now exceeds USD 3 billion in trade. India is a key supplier of pharmaceuticals, medical equipment, and diagnostic technologies, contributing significantly to our healthcare advancements. Our partnership with India is a prime example of how collaboration in health, technology, trade and defence can come together to address pressing challenges and enhance our bilateral ties, driving both healthcare progress and economic prosperity in our nations," added Theodore. As part of its ongoing commitment to the Philippines, Molbio Diagnostics will host a high-impact panel at the 31st Philippine Coalition Against Tuberculosis (PhilCAT) Annual Convention on August 14-15, 2025, in Manila. With a portfolio spanning more than 40 tests for infectious and non-infectious diseases, Molbio combines portability, speed, and accuracy to strengthen public health systems worldwide. Molbio's ongoing studies include a multi-country project funded by the R2D2 TB Network that is exploring novel tongue swab-based molecular diagnostics to improve TB detection among children and people living with HIV/AIDS, the statement said. "By bringing testing closer to communities--whether on remote islands or underserved rural areas--we can close the gap in TB detection and treatment, helping the Philippines achieve its elimination targets. We are committed to strengthening the fight against infectious diseases across the globe, helping countries build more resilient and responsive health systems," said Shiva Sriram, President of Molbio Diagnostics.
Times of Oman
06-08-2025
- Times of Oman
US cancels mRNA vaccine contracts worth $500 million
New York: The US government has decided to halt the funding of 22 projects focused on the development and manufacturing of mRNA-based vaccines that help fight respiratory diseases like COVID-19 and the flu. The decision, announced by Health Secretary Robert F. Kennedy Jr., stemmed from his personal and unproven theories about the efficacy of vaccines and marks the latest attempt in a string of efforts that weave vaccine distrust into US health policy. "We reviewed the science, listened to the experts, and acted," Kennedy said in a statement. The health department's Biomedical Advanced Research and Development Authority (BARDA) is "terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu," he added. In total, the halted projects are worth "nearly $500 million," the Department of Health and Human Services (HHS) said. In a video that he posted on social media, Kennedy criticized mRNA vaccines, explaining the decision to cancel projects being led by the nation's leading pharmaceutical companies, including Pfizer and Moderna, that offer protection against viruses like the flu, COVID-19 and H5N1. "To replace the troubled mRNA programs, we're prioritizing the development of safer, broader vaccine strategies, like whole-virus vaccines and novel platforms that don't collapse when viruses mutate," Kennedy said in the video. "Let me be absolutely clear: HHS supports safe, effective vaccines for every American who wants them," he stressed. The mRNA technology is currently being used for more than infectious disease vaccines, with researchers around the world exploring its use for cancer immunotherapies. In a statement Tuesday, HHS said "other uses of mRNA technology within the department are not impacted by this announcement." Kennedy has been a longtime vaccine critic. Since his appointment as health secretary, he has overseen the remodeling of US health policy. Kennedy has pulled back recommendations around the COVID-19 shots, fired the panel that makes vaccine recommendations, and refused to offer a vigorous endorsement of vaccinations as a measles outbreak worsened.
Times of Oman
01-08-2025
- Times of Oman
Pharma businesses ready with contingency plans faced with US tariffs: Association of Healthcare Providers (India)
New Delhi: Indian pharmaceutical manufacturers are preparing a two-pronged strategy to offset the impact of the soon-to-be-effective 25 per cent US tariff on Indian goods, which includes drug exports, with industry experts anticipating that the move could significantly raise medicine costs in the American market. Girdhar Gyani, Director General of the Association of Healthcare Providers (India), has voiced concern over the financial burden the proposed US tariff would impose on both Indian exporters and American consumers. India currently supplies around 47 per cent of the US pharmaceutical market, largely in the form of affordable generics. "If the United States enforces this 25 per cent tariff, the cost of drug delivery in the US will inevitably rise. Our estimates show that American drug prices could increase by 20 to 25 per cent annually -- a burden of nearly USD 6 to USD 7 billion. It's unclear whether the US healthcare system can absorb such an impact," Gyani said. According to its website, the Association of Healthcare Providers (India) , a non-profit organisation, represents the majority of healthcare providers in India. Despite the initial blow to Indian manufacturers, Gyani stated that industry players are already preparing contingency plans. One such measure is ramping up production in US-based and Mexico-based facilities owned by Indian firms, which, according to Gyani, would bypass the tariff restrictions. "The second approach involves a shift in focus from basic generics to value-added combination drugs. These combination drugs, which offer the convenience of two medicines in one, can be priced higher despite having similar production costs," he noted. The goal is to increase the volume and price range of such drugs, thereby maintaining competitiveness even under the new tariff regime. Gyani also suggested that continued diplomatic engagement between New Delhi and Washington could help mitigate the situation. "Negotiations between the two governments are likely to continue, and we may eventually see a reduction or reconsideration of the tariff policy," he said. The executive order signed by President Donald Trump on Thursday has imposed a flat 25 per cent tariff on all goods from India, with no product-level exemptions. The pharmaceutical sector has been a key pillar of India-US trade relations.
